Regeneron's Eylea Works Better vs Avastin and Lucentis in StudyRegeneron's Eylea Works Better vs Avastin and Lucentis in Study

Regeneron Pharmaceuticals said its drug Eylea (aflibercept) for diabetic macular edema produced significantly greater improvement in visual acuity from baseline to 52 weeks compared with Genentech's Avastin (bevacizumab) and Lucentis (ranibizumab). Reuters Health Information
Source: Medscape Ophthalmology Headlines - Category: Opthalmology Tags: Ophthalmology News Source Type: news